Author: Josephine Maria Kristina Malmevik
Malmevik, Josephine Maria Kristina, 2013 Selective manipulation of microglia using non-viral targeted DNA delivery, Flinders University, School of Medicine
This electronic version is made publicly available by Flinders University in accordance with its open access policy for student theses. Copyright in this thesis remains with the author. This thesis may incorporate third party material which has been used by the author pursuant to Fair Dealing exceptions. If you are the owner of any included third party copyright material and/or you believe that any material has been made available without permission of the copyright owner please contact email@example.com with the details.
Microglia are the resident immunocompetent cells of the central nervous system and are integrally involved in the response to disease and injury. There are currently limited approaches to investigate microglial function in vivo. Targeted delivery of DNA plasmids via cell surface receptors provides one possible means to selectively modify expression of proteins of interest. The potential of this approach has been demonstrated in previous studies using constructs termed immunogenes to selectively transfect neuronal subpopulations. These immunogenes consist of antibodies against a cell surface receptor linked to polycations, which in turn bind the DNA. The broad aim of the present studies was to test whether immunogenes could be used to manipulate protein expression in microglia. The specific aims were to identify a receptor capable of supporting antibody internalisation into microglia, to generate immunogenes incorporating this antibody and test their capacity to transfect microglia in culture and in vivo. Scavenger receptor class B, type I - SR-BI - was initially identified from published studies as a potential target for delivering DNA to glial cells. Using immunohistochemistry, SR-BI was identified in both astrocytes and microglia in mixed glial cultures. However, no immunolabelling of SR-BI was detected in adult rat brain, despite the use of several antigen retrieval protocols. Antibodies directed against an external epitope of SR-BI were highly selectively internalised by microglia both in mixed glial cultures and in the adult brain. Uptake was not seen following injection of two other antibodies into the brain, suggesting that internalisation of this antibody either involved SR-BI that was present but not detected by immunohistochemistry, or resulted from interactions with another microglial protein. This result provided evidence of microglia-specific antibody delivery and prompted studies to test the capacity of immunogenes incorporating the SR-BI antibody to transfect microglia. The initial immunogene was based on constructs used to successfully transfect neurons and contained poly-L-lysine as the polycation. The preparative procedure was subsequently extensively modified to improve immunogene recovery and increase DNA binding. Trials with the final construct resulted in transfection of occasional cells in culture and in the brain as detected from expression of green fluorescent protein encoded by the DNA plasmid. An alternative construct was developed incorporating polyethylenimine as the polycation. This construct produced transfection of both astrocytes and microglia in mixed glial cultures. Transfection efficiencies were much higher than with DNA bound to the polycation alone and similar to that achieved with other non-viral vectors. More significantly, infusions of the immunogene into the hippocampus resulted in transfection of many cells, extending several millimetres from the infusion site. More than 80 percent of transfected cells were immunoreactive for microglial markers. Transfection was not seen with an immunogene incorporating a different antibody or with DNA bound to free polyethylenimine. Transfection was also produced using single intracerebral injections of the SR-BI-based immunogene, albeit in fewer cells. Modifications of the immunogene were tested aimed at promoting release from intracellular vesicles and entry of DNA into the nucleus. These constructs also produced widespread selective transfection, but the modifications did not substantially increase transfection efficiencies. These studies demonstrate that immunogenes can generate highly targeted transfection of microglia in vivo and constitute the first non-viral vector to achieve this outcome. The studies further identify the antibody against SR-BI as a novel carrier to selectively deliver DNA, and potentially other nucleic acids or drugs, to microglia in the brain. Further development of immunogenes or other constructs based on the SR-BI antibody has the potential to provide valuable means for better understanding the functions of microglia in the central nervous system.
Keywords: microglia,targeted gene delivery,non-viral,antibody,immunoporter,immunogene,receptor-mediated gene delivery
Subject: Medical Biochemistry thesis
Thesis type: Doctor of Philosophy
School: School of Medicine
Supervisor: Professor Neil Sims